Target Name: MIR26A1
NCBI ID: G407015
Review Report on MIR26A1 Target / Biomarker Content of Review Report on MIR26A1 Target / Biomarker
MIR26A1
Other Name(s): microRNA 26a-1 | MIRN26A1 | hsa-miR-26a-5p | MicroRNA 26a-1 | MIR26A | hsa-miR-26a-1-3p | hsa-mir-26a-1 | mir-26a-1

miRNA 26a-1 as A Potential Drug Target and Biomarker

MicroRNA (miRNA) 26a-1 is a non-coding RNA molecule that plays a critical role in various biological processes. It is a key regulator of gene expression and has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Despite its importance, little is known about miRNA 26a-1 and its potential drug targets or biomarkers.

In this article, we will explore miRNA 26a-1 and its potential as a drug target and biomarker. We will discuss the current research on miRNA 26a-1 and its function, the potential drug targets it may interact with, and the potential use of miRNA 26a-1 as a biomarker in disease diagnosis and treatment.

Current Research on MiRNA 26a-1

MiRNA 26a-1 is a non-coding RNA molecule that contains 21 amino acid residues. It is expressed in various tissues and cells and has been implicated in various biological processes, including cell growth, apoptosis, and transcriptional regulation.

Studies have shown that miRNA 26a-1 can interact with various protein molecules, including target genes, to regulate their expression levels. miRNA 26a-1 has been shown to interact with the protein translation factor eIF4F and the nuclear protein BAP100, among others.

In addition to its role in gene regulation, miRNA 26a-1 has also been shown to play a role in cellular signaling. It has been shown to regulate the activity of various signaling pathways, including the TGF-β pathway and the PI3K/Akt signaling pathway.

Potential Drug Targets for MiRNA 26a-1

MiRNA 26a-1 has been identified as a potential drug target due to its involvement in various diseases. Its role in cancer development and progression has been well-studied, and several studies have shown that inhibiting miRNA 26a-1 can lead to the inhibition of cancer cell growth and the regression of established tumors.

One of the miRNA 26a-1 drug targets is the TGF-β pathway, which plays a critical role in cancer development. The TGF-β pathway is a complex signaling pathway that is involved in the regulation of cellular growth, differentiation, and inflammation.

Studies have shown that miRNA 26a-1 can inhibit the activity of the TGF-β pathway by regulating the activity of the transcription factor SMAD2. This has led to the inhibition of TGF-β signaling and the suppression of cancer cell growth.

Another potential drug target for miRNA 26a-1 is the PI3K/Akt signaling pathway, which is involved in the regulation of cellular signaling and has been implicated in the development of neurodegenerative diseases.

Studies have shown that miRNA 26a-1 can inhibit the activity of the PI3K/Akt signaling pathway by regulating the activity of the protein kinase BAP100. This has led to the inhibition of PI3K/Akt signaling and the suppression of neurodegenerative disease.

Potential use of MiRNA 26a-1 as a biomarker

MiRNA 26a-1 has the potential to serve as a biomarker for various diseases, including cancer and neurodegenerative diseases. Its role in these diseases has been well-studied, and several studies have shown that the expression levels of miRNA 26a-1 are altered in these diseases.

Studies have shown that miRNA 26a-1 is downregulated in various types of cancer, including breast, ovarian, and colorectal cancers. This downregulation has been shown to lead to the inhibition of cellular signaling pathways, including the TGF-β pathway and the PI3K/Akt signaling pathway.

Similarly, studies have shown that miRNA 26a-1 is upregulated in

Protein Name: MicroRNA 26a-1

The "MIR26A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR26A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144 | MIR3145 | MIR3146 | MIR3147 | MIR3147HG | MIR3148 | MIR3149 | MIR3150A | MIR3150B | MIR3151 | MIR3152 | MIR3153 | MIR3154 | MIR3155A | MIR3155B | MIR3156-1 | MIR3156-2 | MIR3156-3 | MIR3157 | MIR3158-1 | MIR3158-2 | MIR3159 | MIR3160-1 | MIR3160-2